NIPT test

Verifi Prenatal Test The Forefront of Prenatal Screening

Clinical Background
• The verifi Test from Illumina represents a major advance in prenatal testing, providing highly sensitive and specific answers about fetal chromosomal health without the risks associated with invasive procedures, such as amniocentesis or chorionic villus sampling (CVS).

• The verifi Prenatal Test is screens for multiple fetal chromosomal aneuploidies using one tube of maternal blood. The test offers the following benefits:

  • Accurate - Lowest failure rate (0.1%)

  • Reliable - Directly analyzes cell-free fetal and maternal DNA; High detection rate

  • Easy - Noninvasive blood draw, just one tube (7–10 ml); test as early as 10 weeks gestational age (8 weeks of fetal age as determined by date of conception) with no limitations regarding ethnicity, BMI, ART or egg donor cases

  • Fast - Results reported to partner laboratory in 3 - 5 business days after sample receipt (time to report may vary based on partner laboratory providing the test)



Indications for ordering the test
Result Interpretation
Limitations
Specimen and Transport Temperature
Methodology
References